Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Nelson Hayes

Showing results (101-110 of 161) with videos related to

Pageof 17
Sort By:
Journal of Medical Virology|April 20, 2011
Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peg-interferon plus ribavirin therapyTakahiro Azakami, C Nelson Hayes, Hitomi Sezaki, et al.
Journal of Experimental & Clinical Cancer Research : CR|June 27, 2021
Identification and monitoring of mutations in circulating cell-free tumor DNA in hepatocellular carcinoma treated with lenvatinibYasutoshi Fujii, Atsushi Ono, C Nelson Hayes, et al.
Journal of Gastroenterology|January 20, 2011
Factors predictive of sustained virological response following 72 weeks of combination therapy for genotype 1b hepatitis CKazuaki Chayama, C Nelson Hayes, Kentaro Yoshioka, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|November 3, 2010
Accumulation of refractory factors for pegylated interferon plus ribavirin therapy in older female patients with chronic hepatitis CKazuaki Chayama, C Nelson Hayes, Kentaro Yoshioka, et al.
Journal of Hepatology|December 15, 2010
ME3738 enhances the effect of interferon and inhibits hepatitis C virus replication both in vitro and in vivoHiromi Abe, Michio Imamura, Nobuhiko Hiraga, et al.
Journal of Medical Virology|October 5, 2019
Ribavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapyYuhei Saito, Michio Imamura, Takuro Uchida, et al.
Antimicrobial Agents and Chemotherapy|April 5, 2017
Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B VirusMasataka Tsuge, Takuro Uchida, Nobuhiko Hiraga, et al.
The Journal of General Virology|June 20, 2018
Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failureYuji Teraoka, Takuro Uchida, Michio Imamura, et al.
Journal of Gastroenterology and Hepatology|August 6, 2014
Effect of prolonged administration of pegylated interferon/ribavirin therapy in genotypes 2a and 2b: propensity score-matched analysisSatoe Yokoyama, Yoshiiku Kawakami, Michio Imamura, et al.
Antiviral Therapy|December 15, 2010
Amino acid substitutions in core and NS5A regions of the HCV genome can predict virological decrease with pegylated interferon plus ribavirin therapyShosuke Kitamura, Masataka Tsuge, Tsuyoshi Hatakeyama, et al.
Pageof 17

Showing results (101-110 of 161) with videos related to

Sort By:
Pageof 17
Journal of Medical Virology|April 20, 2011
Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peg-interferon plus ribavirin therapyTakahiro Azakami, C Nelson Hayes, Hitomi Sezaki, et al.
Journal of Experimental & Clinical Cancer Research : CR|June 27, 2021
Identification and monitoring of mutations in circulating cell-free tumor DNA in hepatocellular carcinoma treated with lenvatinibYasutoshi Fujii, Atsushi Ono, C Nelson Hayes, et al.
Journal of Gastroenterology|January 20, 2011
Factors predictive of sustained virological response following 72 weeks of combination therapy for genotype 1b hepatitis CKazuaki Chayama, C Nelson Hayes, Kentaro Yoshioka, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|November 3, 2010
Accumulation of refractory factors for pegylated interferon plus ribavirin therapy in older female patients with chronic hepatitis CKazuaki Chayama, C Nelson Hayes, Kentaro Yoshioka, et al.
Journal of Hepatology|December 15, 2010
ME3738 enhances the effect of interferon and inhibits hepatitis C virus replication both in vitro and in vivoHiromi Abe, Michio Imamura, Nobuhiko Hiraga, et al.
Journal of Medical Virology|October 5, 2019
Ribavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapyYuhei Saito, Michio Imamura, Takuro Uchida, et al.
Antimicrobial Agents and Chemotherapy|April 5, 2017
Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B VirusMasataka Tsuge, Takuro Uchida, Nobuhiko Hiraga, et al.
The Journal of General Virology|June 20, 2018
Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failureYuji Teraoka, Takuro Uchida, Michio Imamura, et al.
Journal of Gastroenterology and Hepatology|August 6, 2014
Effect of prolonged administration of pegylated interferon/ribavirin therapy in genotypes 2a and 2b: propensity score-matched analysisSatoe Yokoyama, Yoshiiku Kawakami, Michio Imamura, et al.
Antiviral Therapy|December 15, 2010
Amino acid substitutions in core and NS5A regions of the HCV genome can predict virological decrease with pegylated interferon plus ribavirin therapyShosuke Kitamura, Masataka Tsuge, Tsuyoshi Hatakeyama, et al.
Pageof 17